Argenica Therapeutics reports positive findings from peer-reviewed study of stroke drug ARG-007
Biotechnology company Argenica Therapeutics (ASX: AGN) has announced positive findings from an international peer-reviewed study assessing the safety of its lead drug ARG-007 to reduce brain tissue death after stroke.
Source: smallcaps.com.au